Published on 28 Feb 2024 on GuruFocus.com via Yahoo Finance
Amphastar Pharmaceuticals Inc Reports Robust Revenue Growth and Strong Full-Year Performance
Net Revenues: $178.1 million for Q4 2023, a 32% increase year-over-year.GAAP Net Income: $36.2 million for Q4 2023, with a notable increase from the previous year.Adjusted Non-GAAP Net Income: $46.9 million for Q4 2023, reflecting a more comprehensive view of profitability.GAAP Diluted EPS: $0.68 for Q4 2023, showing earnings growth per share.Product Revenues: Significant contributions from glucagon and Primatene MIST.Operating Cash Flow: $183.5 million for the full year, indicating strong cash generation.Pipeline Development: Multiple ANDAs and biosimilar products in development targeting markets worth billions.
Warning! GuruFocus has detected 2 Warning Sign with AMPH.
On February 28, 2024, Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) released its 8-K filing, revealing a significant uptick in revenue and earnings for the fourth quarter and full year ended December 31, 2023. The company, known for its complex generic and proprietary injectable, inhalation, and intranasal products, as well as insulin API, reported a 32% increase in net revenues for the quarter, amounting to $178.1 million, and a 29% increase for the full year, totaling $644.4 million.